Related Experiment Video
Updated: May 15, 2026

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
[Helicobacter pylori and insulin resistance]
Tomislav Mestrović1, Zora Profozić, Velimir Profozić
1Poliklinika za medicinsku mikrobiologiju s parazitologijom, ginekologiju, internu medicinu, urologiju i medicinu rada Dr. Zora Profozić, Zagreb. tomislav.mestrovic@gmail.com
Abstract:
Extragastric or extraintestinal manifestations of Helicobacter pylori infection attract a lot of attention, and recently this microorganism has also been linked with insulin resistance (IR). The metabolic syndrome consists of several known factors which include IR, abnormal fat metabolism, hypertension, abdominal obesity, proinflammatory and prothrombotic state. H. pylori infection and metabolic syndrome both show increase in prevalence with age, and since IR is a key factor in the pathogenesis of metabolic syndrome, research of a possible correlation between H. pylori infection and IR has intensified in the last decade. A few studies demonstrated a direct link between H. pylori infection and IR, and research studies on the influence of eradication therapy on IR and other metabolic parameters were also conducted. It is necessary to carry out additional prospective studies controlling all the confounding factors that could influence the end result so that the association between H. pylori infection and IR development could be elucidated. So far it is premature to advocate intervention measures in high-risk communities, but if this particular association is confirmed, it could drastically change our understanding of pathophysiology and treatment of IR, type 2 diabetes and metabolic syndrome.
Related Concept Videos
Gastritis II: Pathophysiology
Type II Diabetes II: Pathophysiology
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Peptic Ulcer Disease II: Pathophysiology
Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Oral Hypoglycemic Agents: Biguanides and Glitazones
